ProfileGDS5678 / 1451545_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 75% 74% 79% 74% 61% 70% 73% 74% 76% 73% 76% 74% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3327370
GSM967853U87-EV human glioblastoma xenograft - Control 25.0578275
GSM967854U87-EV human glioblastoma xenograft - Control 34.8224974
GSM967855U87-EV human glioblastoma xenograft - Control 45.6682879
GSM967856U87-EV human glioblastoma xenograft - Control 54.7957874
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7319261
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4091770
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6598673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8925374
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1856376
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6396773
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1598976
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8133674
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0796276